Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis

James R. Dornhoffer, Aaron R. Plitt, Christine M. Lohse, Colin L.W. Driscoll, Brian A. Neff, Aniket A. Saoji, Jamie J. Van Gompel, Michael J. Link, Matthew L. Carlson

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To compare cochlear implant (CI) and auditory brainstem implant (ABI) performance in patients with NF2-related schwannomatosis (NF2) Study Design: Historical cohort. Setting: Tertiary academic center. Patients: A total of 58 devices among 48 patients were studied, including 27 ABIs implanted from 1997 to 2022 and 31 CIs implanted from 2003 to 2022. Three patients had bilateral ABIs, three had bilateral CIs, three had an ABI on one side and a CI on the other, one had a CI that was later replaced with an ipsilateral ABI, and one had an ABI and CI concurrently on the same side. Interventions: CI or ABI ipsilateral to vestibular schwannoma. Main Outcome Measures: Open-set speech perception, consonant-nucleus-consonant word scores, and AzBio sentence in quiet scores. Results: Among all patients, 27 (47%) achieved open-set speech perception, with 35 (61%) daily users at a median of 24 months (interquartile range [IQR], 12–87 mo) after implantation. Comparing outcomes, CIs significantly outperformed ABIs; 24 (77%) CIs achieved open-set speech perception compared with 3 (12%) ABIs, with median consonant-nucleus-consonant and AzBio scores of 31% (IQR, 0–52%) and 57% (IQR, 5–83%), respectively, for CIs, compared with 0% (IQR, 0–0%) and 0% (IQR, 0–0%), respectively, for ABIs. Patients with ABIs were younger at diagnosis and at implantation, had larger tumors, and were more likely to have postoperative facial paresis. Conclusion: Many patients with NF2-associated vestibular schwannoma achieved auditory benefit with either a CI or an ABI; however, outcomes were significantly better in those patients who were able to receive a CI. When disease and anatomy permit, hearing rehabilitation with a CI should be considered over an ABI in these patients. Tumor management strategies that increase the ability to successfully use CIs should be strongly considered given the high risk of losing bilateral functional acoustic hearing in this population.

Original languageEnglish (US)
Pages (from-to)29-35
Number of pages7
JournalCurrent opinion in clinical nutrition and metabolic care
Volume27
Issue number1
DOIs
StatePublished - Nov 1 2023

Keywords

  • ABI
  • Acoustic neuroma
  • Auditory brainstem implant
  • CI
  • Cochlear implant
  • NF2-related schwannomatosis
  • Neurofibromatosis type 2
  • Sensorineural hearing loss
  • Vestibular schwannoma

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this